Skip to content
AnalystLens

Royalty Pharma 8-K Report, Financial Results (Jan 10, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 10, 2025
Period End
January 10, 2025
Security
RPRX
In the record · 2020–202610-K610-Q208-K80

RPRX filed 6 annual reports (10-K), 20 quarterly reports (10-Q) and 80 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Impairment8-K · Dec ’22Dec ’22
  3. Material agreement8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed January 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc furnished a press release on January 10, 2025, ahead of the 43rd Annual J.P.

Morgan Healthcare Conference, giving a preliminary, unaudited update on its 2024 results. The company expects full-year 2024 Portfolio Receipts of approximately $2,800 milliona, at the upper end of its previous guidance range of $2,750 million to $2,800 million. It cites anticipated underlying growth of approximately 13% year-over-year in Royalty Receipts, its recurring cash inflows.

Preliminary full-year 2024 figures are Adjusted EBITDA (non-GAAP) of approximately $2,560 million to $2,570 millionb, Portfolio Cash Flow (non-GAAP) of approximately $2,450 million to $2,455 million, and net cash provided by operating activities of approximately $2,760 million to $2,770 million. The filing states these figures remain subject to change as final adjustments and the audit are completed. Management reported approximately $2.8 billion of royalty transaction deployment in 2024, including a record year for synthetic royalty deals totaling $925 million, and cited announced transactions of approximately $15.5 billion since 2020.

The development-stage pipeline covers over 40 projects, and the late-stage pipeline is described as having un-risk-adjusted peak sales in excess of $21 billionc per year, which could translate to a potential of $1.2 billion annually in new royalties to the company. Key upcoming catalysts named include the aficamten PDUFA target action date of September 26, 2025, and pelacarsen Phase 3 topline results expected in 2025. The release also states that the company announced the acquisition of its external manager and a substantial increase in its share repurchase commitment.

02—Key points

Key Highlights

  1. Expected full-year 2024 Portfolio Receipts of approximately $2,800 million, at the upper end of the $2,750 million to $2,800 million guidance range
  2. Anticipated underlying growth of approximately 13% year-over-year in Royalty Receipts
  3. Preliminary 2024 Adjusted EBITDA (non-GAAP) of approximately $2,560 million to $2,570 million and Portfolio Cash Flow (non-GAAP) of approximately $2,450 million to $2,455 million
  4. Approximately $2.8 billion deployed in royalty transactions in 2024, including a record $925 million in synthetic royalty deals
  5. Late-stage pipeline with un-risk-adjusted peak sales in excess of $21 billion per year, potentially translating to $1.2 billion annually in new royalties
  6. Announced acquisition of the external manager and a substantial increase in the share repurchase commitment
  7. Upcoming catalysts include the aficamten PDUFA date of September 26, 2025 and pelacarsen Phase 3 topline results expected in 2025

03—Questions

Frequently Asked Questions

  1. What did Royalty Pharma report for full-year 2024 Portfolio Receipts?

    The company expects Portfolio Receipts of approximately $2,800 million for 2024, at the upper end of its previous guidance range of $2,750 million to $2,800 million. These are preliminary, unaudited figures that remain subject to change.

  2. How did Royalty Receipts perform in 2024?

    Royalty Pharma anticipates underlying growth of approximately 13% year-over-year in Royalty Receipts, which it describes as its recurring cash inflows.

  3. What are the expected 2024 profitability and cash flow measures?

    Preliminary 2024 estimates are Adjusted EBITDA (non-GAAP) of approximately $2,560 million to $2,570 million, Portfolio Cash Flow (non-GAAP) of approximately $2,450 million to $2,455 million, and net cash provided by operating activities of approximately $2,760 million to $2,770 million. The company notes that Adjusted EBITDA and Portfolio Cash Flow are liquidity measures tied to credit agreement covenants.

  4. What upcoming events could affect future royalty income?

    The filing cites the aficamten PDUFA target action date of September 26, 2025, and pelacarsen Phase 3 topline results expected in 2025. It also says the late-stage pipeline could add approximately $1.2 billion annually in new royalties at potential peak sales.

  5. What shareholder-related actions did the company announce?

    The press release states that Royalty Pharma announced the acquisition of its external manager and a substantial increase in its commitment to share repurchases, which the CEO described as transformative steps to enhance shareholder value.

04—Continue

← View all 8-K filings